Granted Patent
B2
US 9,585,932 · App. 13/792,336 · Granted Mar 7, 2017
Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders
Assignee:
Peter C. Dowling
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The described invention provides methods and kits for administering an EPO-derived peptide to a subject suffering from a neurodegenerative disease. The EPO-derived peptide delays the onset and/or progression of a neurodegenerative disease, limits cognitive impairment in, and prolongs the survival of, subjects suffering from a neurodegenerative disease.
Claims (2)
1. A kit comprising a composition comprising a cyclic EPO-derived peptide of SEQ ID NO: 1.
2. The kit according to claim 1 , wherein the composition further comprises a pharmaceutically acceptable excipient.
Assignments (3)
UNDIVIDED ONE-HALF (50%) INTEREST
Recorded Dec 24, 2020
From: UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
To: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
Reel/Frame 054849/0507 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 24, 2019
From: DOWLING, PETER C.
To: THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
Reel/Frame 050811/0748 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 18, 2016
From: LU, WEI; YUAN, RUI RONG
To: DOWLING, PETER C.
Reel/Frame 039381/0364 →
Continuity (4)
Continuation In Part
11913038
Provisional Application
60676592
· Apr 29, 2005
Related Publication
20160271206A9
· Sep 22, 2016